Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Jiangsu HengRui Medicine Co., Ltd.
Fluzoparib (SHR-3162) is an orally available, small molecule inhibitor of poly-adenosine diphosphate \[ADP\] ribose polymerase (PARP) 1/2 being developed for treatment of BRCA1/2-mutant solid tumor. The tolerability, safety and PK of fluzoparib has been evaluated in Phase 1 study. An oral formulation is the focus of current development efforts.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed diagnosis of high grade serous or Grade 2/3 endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer;
Confirmed documented BRCA1/2 mutation;
Received 2\~4 prior chemotherapy regimens. Non-chemotherapy regimens and maintenance therapies administered as single agent treatment will not count as a chemotherapy regimen;
Relapsed/progressive disease as confirmed by radiologic assessment;
Have measurable disease as defined by RECIST v1.1.
You may not be if
Any previous treatment with a PARP inhibitor;
Patient with any other malignancy which has been active or treated within the previous 5 years;
Patients with symptomatic uncontrolled brain metastases;
Patients unable to swallow orally administered medication.